These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 22966871)

  • 21. [Pre-exposure prophylaxis for HIV transmission? No, unless].
    Boeke AJ; Heijnen AM
    Ned Tijdschr Geneeskd; 2013; 157(27):A6359. PubMed ID: 23838404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical pharmacology of antiretrovirals for HIV prevention.
    Hendrix CW
    Curr Opin HIV AIDS; 2012 Nov; 7(6):498-504. PubMed ID: 22964888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of tenofovir disoproxil fumarate and emtricitabine combination in HIV-infected patients.
    Gazzard BG
    Expert Opin Pharmacother; 2006 Apr; 7(6):793-802. PubMed ID: 16556093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a guide to its use in HIV-1 infection.
    Lyseng-Williamson KA; Scott LJ
    Clin Drug Investig; 2012 Oct; 32(10):715-22. PubMed ID: 22921088
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV preexposure prophylaxis: new data and potential use.
    Celum CL
    Top Antivir Med; 2011 Dec; 19(5):181-5. PubMed ID: 22298887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and topical vaginal effects of two tenofovir gels in rabbits.
    Clark MR; Friend DR
    AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1458-66. PubMed ID: 22394281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue.
    Dobard C; Sharma S; Martin A; Pau CP; Holder A; Kuklenyik Z; Lipscomb J; Hanson DL; Smith J; Novembre FJ; García-Lerma JG; Heneine W
    J Virol; 2012 Jan; 86(2):718-25. PubMed ID: 22072766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.
    Anderson PL; Kiser JJ; Gardner EM; Rower JE; Meditz A; Grant RM
    J Antimicrob Chemother; 2011 Feb; 66(2):240-50. PubMed ID: 21118913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
    Celum C; Morrow RA; Donnell D; Hong T; Hendrix CW; Thomas KK; Fife KH; Nakku-Joloba E; Mujugira A; Baeten JM;
    Ann Intern Med; 2014 Jul; 161(1):11-9. PubMed ID: 24979446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Knowledge of and opinions on HIV preexposure prophylaxis among front-line service providers at Canadian AIDS service organizations.
    Senn H; Wilton J; Sharma M; Fowler S; Tan DH
    AIDS Res Hum Retroviruses; 2013 Sep; 29(9):1183-9. PubMed ID: 23731254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Models for predicting effective HIV chemoprevention in women.
    Nicol MR; Emerson CW; Prince HM; Nelson JA; Fedoriw Y; Sykes C; Geller EJ; Patterson KB; Cohen MS; Kashuba AD
    J Acquir Immune Defic Syndr; 2015 Apr; 68(4):369-76. PubMed ID: 25501616
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate.
    Anton PA; Cranston RD; Kashuba A; Hendrix CW; Bumpus NN; Richardson-Harman N; Elliott J; Janocko L; Khanukhova E; Dennis R; Cumberland WG; Ju C; Carballo-Diéguez A; Mauck C; McGowan I
    AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1412-21. PubMed ID: 22943559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice.
    Denton PW; Krisko JF; Powell DA; Mathias M; Kwak YT; Martinez-Torres F; Zou W; Payne DA; Estes JD; Garcia JV
    PLoS One; 2010 Jan; 5(1):e8829. PubMed ID: 20098623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tenofovir-based preexposure prophylaxis for HIV infection among African women.
    Marrazzo JM; Ramjee G; Richardson BA; Gomez K; Mgodi N; Nair G; Palanee T; Nakabiito C; van der Straten A; Noguchi L; Hendrix CW; Dai JY; Ganesh S; Mkhize B; Taljaard M; Parikh UM; Piper J; Mâsse B; Grossman C; Rooney J; Schwartz JL; Watts H; Marzinke MA; Hillier SL; McGowan IM; Chirenje ZM;
    N Engl J Med; 2015 Feb; 372(6):509-18. PubMed ID: 25651245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The British HIV Association/British Association for Sexual Health and HIV Position Statement on pre-exposure prophylaxis in the UK.
    McCormack S; Fidler S; Fisher M; ;
    Int J STD AIDS; 2012 Jan; 23(1):1-4. PubMed ID: 22362679
    [No Abstract]   [Full Text] [Related]  

  • 36. Inefficient vaginal transmission of tenofovir-resistant HIV-1.
    Chateau M; Swanson MD; Garcia JV
    J Virol; 2013 Jan; 87(2):1274-7. PubMed ID: 23115295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
    Sax PE; Wohl D; Yin MT; Post F; DeJesus E; Saag M; Pozniak A; Thompson M; Podzamczer D; Molina JM; Oka S; Koenig E; Trottier B; Andrade-Villanueva J; Crofoot G; Custodio JM; Plummer A; Zhong L; Cao H; Martin H; Callebaut C; Cheng AK; Fordyce MW; McCallister S;
    Lancet; 2015 Jun; 385(9987):2606-15. PubMed ID: 25890673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emtricitabine/tenofovir disoproxil fumarate.
    Dando TM; Wagstaff AJ
    Drugs; 2004; 64(18):2075-82; discussion 2083-4. PubMed ID: 15341498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine.
    Parikh UM; Dobard C; Sharma S; Cong ME; Jia H; Martin A; Pau CP; Hanson DL; Guenthner P; Smith J; Kersh E; Garcia-Lerma JG; Novembre FJ; Otten R; Folks T; Heneine W
    J Virol; 2009 Oct; 83(20):10358-65. PubMed ID: 19656878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission.
    Patterson KB; Prince HA; Kraft E; Jenkins AJ; Shaheen NJ; Rooney JF; Cohen MS; Kashuba AD
    Sci Transl Med; 2011 Dec; 3(112):112re4. PubMed ID: 22158861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.